MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the publication of new …
Cowen analysts came out today with an optimistic view on the oncology company MEI Pharma Inc (NASDAQ:MEIP) and vaccine development company Genocea Biosciences Inc (NASDAQ:GNCA), as the iShares Nasdaq …
Now that Wall Street is in the second half of the year, analysts are anticipating updates and announcements about pipeline drugs from biopharmaceutical …
In a research report published Wednesday, Cantor analyst Daniel Brims reiterated a Buy rating on shares of MEI Pharma Inc (NASDAQ:MEIP), with a price …
MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced results for its fiscal year …
In a research report released Friday, Wedbush analyst David Nierengarten reiterated a Neutral rating on MEI Pharma Inc (NASDAQ:MEIP) with a $3 price target, …
I stumbled upon MEI Pharma Inc (NASDAQ:MEIP) after reading over the American Society of Hematology (ASH) abstracts at the end of last year. …
Written by Scott Matusow. Sometimes in biotech, things do not go as expected.
The investment firm Cantor Fitzgerald lowered its price target today on MEI Pharma Inc (NASDAQ:MEIP) to $7.00 (from $14.
MEI Pharma Inc (NASDAQ:MEIP) shares are down almost 70% today following the news that the company's cancer drug Pracinostat failed to meet the primary endpoint of a Phase …
